Regulus Therapeutics is a San Diego-based biopharmaceutical company focused on developing microRNA-targeted drugs for orphan kidney diseases, including its candidate RGLS8429 for autosomal dominant polycystic kidney disease. The company went public on October 4, 2012, and has 28 employees.
Regulus Therapeutics (RGLS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Regulus Therapeutics's actual EPS was -$0.20, beating the estimate of -$0.21 per share, resulting in a 6.63% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
